Welcome to Helix Talk, an educational podcast for healthcare students and providers covering real-life clinical pearls, professional pharmacy topics, and drug therapy discussions.

This podcast is provided by pharmacists and faculty members at Rosal Franklin University College of Pharmacy.

This podcast contains general information for educational purposes only. This is not professional

advice and should not be used in lieu of obtaining advice from a qualified health care provider.

And now on to the show. Welcome to Helix Talk episode 105. I'm your co-host Dr. Kane.

And I'm Dr. Patel. And the title of today's episode is unraveling

the mystery of P2Y-12 inhibitors, clinical pearls, and comparative evidence. And today we're talking

about the P2-Y-12 inhibitors, basically a class review and what a typical clinician is going to need

to know about really these three oral agents that are commonly used on the market.

And we should keep in mind that you may hear different names of these pharmacologic drugs.

It could be P2Y12 receptor antagonist. It could be P2Y12 inhibitor. It could be ADP receptor antagonist,

although there are technically other ADP receptor antagonists, then these

3 P2Y12 inhibitors. And then some may also known these as thionoparidine because of the chemical

structure of the drugs. And in all fairness to that last one, Tycagralore, the third one that we'll be

talking about, isn't even in that drug category per se, because structurally it's

different that we will talk about. So really, P2y212 receptor antagonist or P2y2y12 inhibitor is probably the

most appropriate term for what we're trying to classify today. And so the first agent is

Klpito-Gro, brand name Plavix. That was the first one available of this category in 1997.

And then a couple of me-toes came up and those were prasagrel or effiant in 2009.

And psychagrelour, Berlenta, that came in 2011.

And we will acknowledge that there's a fourth agent that's IV only that we're not going to

talk about today because really we're comparing these chronic oral P fourth agent that's IV only that we're not going to talk about today

...